Determinants of anti-PD-1 response and resistance in clear cell renal cell carcinoma

Au, L; Hatipoglu, E; de Massy, MR; Litchfield, K; Beattie, G; Rowan, A; Schnidrig, D; Thompson, R; Byrne, F; Horswell, S; Fotiadis, N; Hazell, S; Nicol, D; Shepherd, STC; Fendler, A; Mason, R; Del Rosario, L; Edmonds, K; Lingard, K; Sarker, S; Mangwende, M; Carlyle, E; Attig, J; Joshi, K; Uddin, I; Becker, PD; Sunderland, MW; Akarca, A; Puccio, I; Yang, WW; Lund, T; Dhillon, K; Vasquez, MD; Ghorani, E; Xu, H; Spencer, C; Lopez, JI; Green, A; Mahadeva, U; Borg, E; Mitchison, M; Moore, DA; Proctor, I; Falzon, M; Pickering, L; Furness, AJS; Reading, JL; Salgado, R; Marafioti, T; Jamal-Hanjani, M; PEACE Consortium; Kassiotis, G; Chain, B; Larkin, J; Swanton, C; Quezada, SA; Turajlic, S; TRACERx Renal Consortium

Author(s): Au, L; Hatipoglu, E; de Massy, MR; Litchfield, K; Beattie, G; Rowan, A; Schnidrig, D; Thompson, R; Byrne, F; Horswell, S; Fotiadis, N; Hazell, S; Nicol, D; Shepherd, STC; Fendler, A; Mason, R; Del Rosario, L; Edmonds, K; Lingard, K; Sarker, S; Mangwende, M; Carlyle, E; Attig, J; Joshi, K; Uddin, I; Becker, PD; Sunderland, MW; Akarca, A; Puccio, I; Yang, WW; Lund, T; Dhillon, K; Vasquez, MD; Ghorani, E; Xu, H; Spencer, C; Lopez, JI; Green, A; Mahadeva, U; Borg, E; Mitchison, M; Moore, DA; Proctor, I; Falzon, M; Pickering, L; Furness, AJS; Reading, JL; Salgado, R; Marafioti, T; Jamal-Hanjani, M; PEACE Consortium; Kassiotis, G; Chain, B; Larkin, J; Swanton, C; Quezada, SA; Turajlic, S; TRACERx Renal Consortium;
Details: Publication Year 2021-11-08,Volume 39,Issue #11,Page 1497-1518.e11
Journal Title: Cancer Cell
Publication Type: Research article
Abstract: ADAPTeR is a prospective, phase II study of nivolumab (anti-PD-1) in 15 treatment-naive patients (115 multiregion tumor samples) with metastatic clear cell renal cell carcinoma (ccRCC) aiming to understand the mechanism underpinning therapeutic response. Genomic analyses show no correlation between tumor molecular features and response, whereas ccRCC-specific human endogenous retrovirus expression indirectly correlates with clinical response. T cell receptor (TCR) analysis reveals a significantly higher number of expanded TCR clones pre-treatment in responders suggesting pre-existing immunity. Maintenance of highly similar clusters of TCRs post-treatment predict response, suggesting ongoing antigen engagement and survival of families of T cells likely recognizing the same antigens. In responders, nivolumab-bound CD8(+) T cells are expanded and express GZMK/B. Our data suggest nivolumab drives both maintenance and replacement of previously expanded T cell clones, but only maintenance correlates with response. We hypothesize that maintenance and boosting of a pre-existing response is a key element of anti-PD-1 mode of action.
Keywords: CD8-Positive T-Lymphocytes; Carcinoma, Renal Cell/*drug therapy/genetics; Clinical Trials, Phase II as Topic; *Drug Resistance, Neoplasm; Endogenous Retroviruses/genetics; Gene Expression Profiling/methods; Genomics/methods; Humans; Immune Checkpoint Inhibitors/*administration & dosage/pharmacology; Kidney Neoplasms/*drug therapy/genetics; Nivolumab/*administration & dosage/pharmacology; Prospective Studies; Receptors, Antigen, T-Cell/*genetics; Sequence Analysis, RNA; Single-Cell Analysis; Tumor Escape; Tumor Microenvironment; Exome Sequencing; T cell receptor; TCR clonal maintenance; TCR clonal replacement; anti-PD-1; autopsy; clear cell renal cell carcinoma; human endogenous retrovirus; multiregion; nivolumab
Department(s): Laboratory Research
PubMed ID: 34715028
Publisher's Version: https://doi.org/10.1016/j.ccell.2021.10.001
Open Access at Publisher's Site: https://doi.org/10.1016/j.ccell.2021.10.001
Terms of Use/Rights Notice: Refer to copyright notice on published article.

Creation Date: 2025-05-23 08:13:58

Last Modified: 2025-05-23 08:15:07